These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9797244)
1. In vitro activity of a new polyene, SPA-S-843, against yeasts. Rimaroli C; Bruzzese T Antimicrob Agents Chemother; 1998 Nov; 42(11):3012-3. PubMed ID: 9797244 [TBL] [Abstract][Full Text] [Related]
2. Antimycotic activity in vitro and in vivo of a new hydrosoluble polyene antibiotic. Strippoli V; Evangelista AM; Simonetti N Farmaco Sci; 1976 Dec; 31(12):891-900. PubMed ID: 1017483 [TBL] [Abstract][Full Text] [Related]
3. Overview of SPA-S-843 in vitro activity against filamentous fungi. Rimaroli C; Bruzzese T Chemotherapy; 2000; 46(1):28-35. PubMed ID: 10601795 [TBL] [Abstract][Full Text] [Related]
4. [Study of the in vitro sensitivity of yeasts with the ATB-Fungus system]. Martínez MM; Mendaza P; Daza RM; Sánchez G; Martín P; Martín JE; Portero F Rev Esp Quimioter; 1998 Sep; 11(3):251-3. PubMed ID: 9795312 [No Abstract] [Full Text] [Related]
5. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Morace G; Manzara S; Dettori G Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239 [TBL] [Abstract][Full Text] [Related]
6. Non-emergence of polyene-resistant yeasts: an hypothesis. Hamilton-Miller JM Microbios; 1974; 10A SUPPL(41):91-5. PubMed ID: 4281851 [No Abstract] [Full Text] [Related]
7. [Evaluation of a new method for antifungal drugs susceptibility testing to yeasts]. Ishigaki S; Kawakami S; Ono Y; Miyazawa Y Kansenshogaku Zasshi; 2000 Mar; 74(3):221-30. PubMed ID: 10783576 [TBL] [Abstract][Full Text] [Related]
8. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817 [TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans. Strippoli V; D'Auria FD; Simonetti N; Basti D; Bruzzese T Infection; 1997; 25(1):27-31. PubMed ID: 9039534 [TBL] [Abstract][Full Text] [Related]
10. In vitro combination therapy with isavuconazole against Candida spp. Katragkou A; McCarthy M; Meletiadis J; Hussain K; Moradi PW; Strauss GE; Myint KL; Zaw MH; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ; Petraitis V Med Mycol; 2017 Nov; 55(8):859-868. PubMed ID: 28204571 [TBL] [Abstract][Full Text] [Related]
11. [The sensitivity of yeasts from the Candida genus isolated from cancer patients to polyene antifungals]. Alves SH; Cury AE Rev Inst Med Trop Sao Paulo; 1992; 34(3):251-4. PubMed ID: 1342079 [TBL] [Abstract][Full Text] [Related]
12. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts. Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421 [TBL] [Abstract][Full Text] [Related]
13. A comparative in vitro study of amphotericin B 1 clotrimazole and 5-fluorocytosine against clinically isolated yeasts. Hamilton-Miller JM Sabouraudia; 1972 Nov; 10(3):276-83. PubMed ID: 4565443 [No Abstract] [Full Text] [Related]
14. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period. Kucukates E; Erturan Z; Susever S; Yegenoglu Y APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609 [TBL] [Abstract][Full Text] [Related]
15. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410 [TBL] [Abstract][Full Text] [Related]
16. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Mesa-Arango AC; Trevijano-Contador N; Román E; Sánchez-Fresneda R; Casas C; Herrero E; Argüelles JC; Pla J; Cuenca-Estrella M; Zaragoza O Antimicrob Agents Chemother; 2014 Nov; 58(11):6627-38. PubMed ID: 25155595 [TBL] [Abstract][Full Text] [Related]
17. Synergistic fungicidal activity of the lipopeptide bacillomycin D with amphotericin B against pathogenic Candida species. Tabbene O; Di Grazia A; Azaiez S; Ben Slimene I; Elkahoui S; Alfeddy MN; Casciaro B; Luca V; Limam F; Mangoni ML FEMS Yeast Res; 2015 Jun; 15(4):fov022. PubMed ID: 25956541 [TBL] [Abstract][Full Text] [Related]
18. Exposure to subtherapeutic concentrations of polyene antifungals suppresses the adherence of Candida species to denture acrylic. Egusa H; Ellepola AN; Nikawa H; Hamada T; Samaranayake LP Chemotherapy; 2000; 46(4):267-74. PubMed ID: 10859432 [TBL] [Abstract][Full Text] [Related]
19. Anticandidal activity of SPA-S-843, a new polyenic drug. Strippoli V; D'Auria FD; Simonetti G; Bruzzese T; Simonetti N J Antimicrob Chemother; 2000 Feb; 45(2):235-7. PubMed ID: 10660508 [TBL] [Abstract][Full Text] [Related]